Skip to content
Accessibility help
Search NICE…
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Deferred
Awaiting development
Topic prioritisation
Filter (2 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (4)
Type
(
1 selected
)
Type
Guidance (294)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (8)
Health technology evaluations (19)
HealthTech guidance (10)
Highly specialised technologies guidance (4)
Interventional procedures guidance (12)
Medical technologies guidance (9)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (294)
Apply filters
Showing 71 to 80 of 294
Sort by
Title
Date
Apply sorting
Type: Guidance
`Remove $Type: Guidance filter`
Guidance programme: Technology appraisal guidance
`Remove $Guidance programme: Technology appraisal guidance filter`
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]
Technology appraisal guidance
TBC
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
Technology appraisal guidance
TBC
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]
Technology appraisal guidance
18 June 2026
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779) [ID6326]
Technology appraisal guidance
23 July 2026
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]
Technology appraisal guidance
TBC
Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]
Technology appraisal guidance
TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
Technology appraisal guidance
TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]
Technology appraisal guidance
TBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]
Technology appraisal guidance
TBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]
Technology appraisal guidance
TBC
Previous page
1
…
6
7
Current page
8
9
10
…
30
Page
8
of
30
Next page
Results per page
10
25
50
All
Back to top